the risk of hepatocellular carcinoma after directly acting antivirals for hepatitis c virus treatment in liver transplanted patients: is it real?
نویسندگان
چکیده
introduction since directly acting antivirals (daas) for treatment of hepatitis c virus (hcv) were introduced, conflicting data emerged about the risk of hepatocellular carcinoma (hcc) after interferon (ifn)-free treatments. we present a case of recurrent, extra-hepatic hcc in a liver-transplanted patient soon after successful treatment with daas, along with a short review of literature. conclusions overall, nine studies have been published about the risk of hcc after daas. patients with previous hcc should be carefully investigated to confirm complete hcc remission before starting, and proactive follow-up should be performed after daa treatment. case presentation in 2010, a 53-year old man, affected by chronic hcv (genotype 1) infection and decompensated cirrhosis, underwent liver resection for hcc and subsequently received orthotopic liver transplantation. then, hcv relapsed and, in 2013, he was treated with pegylated-ifn plus ribavirin; but response was null. in 2014, he was treated with daclatasvir plus simeprevir to reach sustained virological response. at baseline and at the end of hcv treatment, computed tomography (ct) scan of abdomen excluded any lesions suspected for hcc. however, alpha-fetoprotein was 2.9 ng/ml before daas, increasing up to 183.1 ng/ml at week-24 of follow-up after the completion of therapy. therefore, ct scan of abdomen was performed again, showing two splenic hcc lesions.
منابع مشابه
The Risk of Hepatocellular Carcinoma After Directly Acting Antivirals for Hepatitis C Virus Treatment in Liver Transplanted Patients: Is It Real?
INTRODUCTION Since directly acting antivirals (DAAs) for treatment of hepatitis C virus (HCV) were introduced, conflicting data emerged about the risk of hepatocellular carcinoma (HCC) after interferon (IFN)-free treatments. We present a case of recurrent, extra-hepatic HCC in a liver-transplanted patient soon after successful treatment with DAAs, along with a short review of literature. CASE...
متن کاملDirectly acting antivirals against hepatitis C virus.
The approval of directly acting antivirals (DAA) for the treatment of chronic hepatitis C virus (HCV) infection will represent a major breakthrough for the 180 million persons infected worldwide. Paradoxically, hepatitis C is the only human chronic viral disease that can be cured, as all other pathogenic viruses infecting humans either display self-limited courses or establish non-eradicable pe...
متن کاملThe use of Direct-Acting Antivirals in Hepatitis C Virus-Infected Patients with Hepatocellular Carcinoma
531. Results of a Hepatitis C Virus Screening Program of the 1945-1965 Birth Cohort in a Large Emergency Department in New Jersey Julia Kang Cornett, MD; Vimal Bodiwala, MD; Victor Razuk, BS; Devangi Shukla, BS, MBS and Navaneeth Narayanan, Pharm D, BCPS; Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, Department of Pharmacy Practice and Administration, Rutgers Ernest Mar...
متن کاملHepatitis C Virus and Hepatocellular Carcinoma: Pathogenetic Mechanisms and Impact of Direct-Acting Antivirals
Introduction Globally, between 64 and 103 million people are chronically infected with Hepatitis C virus (HCV), with more than 4.6 million people in the United States and is associated with more than 15.000 deaths annually. Chronic infection can result in cirrhosis and hepatocellular carcinoma. Explanation Epidemiological studies have indicated that persistent infection with hepatitis C virus...
متن کاملOccult Hepatitis B and Risk of Reactivation After Hepatitis C Treatment With Direct-Acting Antivirals.
متن کامل
Liver decompensation predicts ribavirin overexposure in hepatitis C virus patients treated with direct-acting antivirals
AIM To determine whether ribavirin (RBV) concentrations differ according to cirrhosis stage among cirrhotic patients treated with interferon-free regimens. METHODS We included patients with hepatitis C virus and cirrhosis [Child-Pugh (CP) A or B], Glomerular Filtration Rate ≥ 60 mL/min, who started therapy with DAAs and weight-based RBV between October 2014 and February 2016. RBV plasma level...
متن کاملمنابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
hepatitis monthlyجلد ۱۶، شماره ۱۱، صفحات ۰-۰
میزبانی شده توسط پلتفرم ابری doprax.com
copyright © 2015-2023